Similar to NSCLC with LKB1 inactivation, NSCLC with disruption of the KEAP1-NRF2 pathway is widely known respond poorly to monotherapy with anti-PD-1/PD-L1 antibodies. Here, KEAP1 is linked to non-small cell lung carcinoma.